This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC

This study has been completed.
Information provided by (Responsible Party):
Syndax Pharmaceuticals Identifier:
First received: January 25, 2008
Last updated: April 18, 2012
Last verified: April 2012
The purpose of this study is to evaluate the safety and efficacy of SNDX-275 in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer.

Condition Intervention Phase
Non-Small-Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung Drug: entinostat Drug: SNDX-275 Drug: erlotinib Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease

Resource links provided by NLM:

Further study details as provided by Syndax Pharmaceuticals:

Primary Outcome Measures:
  • Progression-free survival rate [ Time Frame: 4 months ]

Secondary Outcome Measures:
  • Progressive-free survival rate [ Time Frame: 6 months ]
  • Evaluate safety and tolerability of SNDX-275 in combination with erlotinib [ Time Frame: from date of randomization to discontinuation due to disease progression or intolerable AE ]
  • Evaluate pharmacokinetics of SNDX-275 in combination with erlotinib [ Time Frame: From randomization thru day 15 of Cycle 4 of study treatment ]

Enrollment: 132
Study Start Date: December 2007
Study Completion Date: March 2012
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation
Drug: entinostat

Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)

Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)

Drug: erlotinib
erlotinib 150mg PO QD
Other Name: Tarceva
Experimental: 2
erlotinib (Tarceva) and entinostat
Drug: SNDX-275
entinostat 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles
Drug: erlotinib
erlotinib 150mg PO QD
Other Name: Tarceva
Placebo Comparator: 3

erlotinib (Tarceva) and matched Placebo

patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles

Drug: erlotinib
erlotinib 150mg PO QD
Other Name: Tarceva


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Cytologically or histologically confirmed NSCLC of stage IIIb or IV
  • Received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy regimens for advanced NSCLC (that did not include erlotinib and valporic acid) and progressed based on radiologic evidence
  • At least 1 measurable lesion by conventional or spiral CT scan
  • ECOG performance score of 0, 1, or 2 and life expectancy of at least 6 months
  • Paraffin-embedded tumor specimen available for correlative studies
  • Male or female over 18 years of age
  • Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; ANC ≥ 1.5 x 109/L without the use of hematopoietic growth factors
  • Bilirubin and creatinine less than 2 times the upper limit of normal for the institution
  • Albumin ≥ 2.5 /dL
  • AST and ALT less than 3 times the upper limit of normal for the institution
  • Prothrombin time less than 1.5 times the upper limit of normal for the institution
  • Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)
  • Willing to use accepted and effective methods of contraception during the study (both men and women as appropriate) and for 3 months after the last dose of SNDX-275
  • Patient or legally acceptable representative has granted written informed consent before any study-specific procedure (including special screening tests) are performed

Exclusion Criteria

  • Prior stem cell transplant
  • Clinical evidence of CNS involvement
  • Prior treatment with an HDAC inhibitor or an EGFR inhibitor
  • Currently taking known inhibitors of CYPA4, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, ≥ 10 mg prednisone, and voriconazole
  • Current use of valporic acid
  • Prior exposure to SNDX-275
  • Systemic chemotherapy, radiotherapy, or treatment with an investigational agent without recovery to at least grade 1 or baseline before study drug administration
  • Daily treatment with ≥ 10 mg prednisone within 28 days before study drug administration
  • Local or whole brain palliative radiotherapy within 14 days before study drug administration
  • Currently active second malignancy, or any malignancy within the last 5 years other than cured basal or squamous cell skin carcinoma, cervical carcinoma in situ, carcinoma in situ of the bladder, or papillary thyroid cancer
  • Inability to swallow oral medications or a gastrointestinal malabsorption condition
  • Acute infection requiring IV antibiotics, antivirals, or antifungals within 14 days before study drug administration
  • Known HIV infection, or active hepatitis B or C infection
  • Another serious or uncontrolled medical condition within 90 days before study drug administration such as acute myocardial infarction, angina, ventricular arrhythmias, hypertension, diabetes mellitus, or renal or hepatic insufficiency
  • Known hypersensitivity to benzamides
  • Women who are currently pregnant or breast-feeding
  • Patient currently is enrolled in (or completed within 28 days before study drug administration) another investigational drug study
  • Patient has any kind of medical, psychiatric, or behavioral disorder that places the patient at increased risk for study participation or compromises the ability of the patient to give written informed consent and/or to comply with study procedures and requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00602030

  Show 30 Study Locations
Sponsors and Collaborators
Syndax Pharmaceuticals
Principal Investigator: Samir Witta, MD Rocky Mountain Cancer Centers
Principal Investigator: Kartik Konduri, MD Texas Oncology - Sammons Cancer Center
Principal Investigator: Robert Raju, MD Dayton Oncology
  More Information

Responsible Party: Syndax Pharmaceuticals Identifier: NCT00602030     History of Changes
Other Study ID Numbers: SNDX-275-0401
Study First Received: January 25, 2008
Last Updated: April 18, 2012

Keywords provided by Syndax Pharmaceuticals:
lung cancer
lung neoplasms

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Histone Deacetylase Inhibitors processed this record on September 21, 2017